Key result
Stage 4 cardiac damage is linked to ~28-fold higher in-hospital mortality after SAVR, exceeding TAVR.
Why the study?
To determine whether cardiac damage based on hospital discharge codes is associated with in-hospital outcomes in patients with aortic stenosis.
Does advanced cardiac damage stage increase in-hospital mortality, length of stay, and cost in patients with aortic stenosis?
Does advanced cardiac damage stage increase in-hospital mortality, length of stay, and cost in patients with aortic stenosis?
Higher stages of cardiac damage in patients with aortic stenosis are strongly associated with increased in-hospital mortality, length of stay, and costs, particularly among those undergoing surgical aortic valve replacement.
Stage 4 cardiac damage signals higher SAVR mortality risk in aortic stenosis; hypothesis-generating for TAVR preference pending prospective validation.
INTRODUCTION: The objective of this study is to determine if cardiac damage based on hospital discharge codes is associated with in-hospital outcomes in patients with aortic stenosis (AS). METHODS: We conducted a retrospective cohort study of hospital admissions between 2016 and 2021 with a diagnosis of AS in the National Inpatient Sample (NIS). The cardiac damage stages 0-4 were determined based on hospital discharge codes. Logistic and linear regressions were used to determine the association between cardiac stage and in-hospital mortality, length of stay (LoS) and cost. RESULTS: A total of 2,980,150 hospital admissions were included in the analysis (82.5% conservative management, 11.2% transcatheter aortic valve replacement [TAVR], 6.3% surgical aortic valve replacement [SAVR]). The association between cardiac damage stage and in-hospital outcome was most significant for patients who had SAVR treatment (stage 4 vs. stage 0: mortality OR 27.70 95% CI 17.35-35.17, LoS 7.34 95% CI 6.34-8.35, cost 70,710 95% CI 65,110-76,310) compared to TAVR treatment (stage 4 vs. stage 0: mortality OR 9.15 95% CI 5.52-15.15, LoS 6.27 95% CI 5.63-6.90, cost 28,384 25,084 to 31,684) and conservative treatment (stage 4 vs. stage 0: mortality OR 3.55 95% CI 3.13-4.04, LoS 2.09 95% CI 1.87 to 2.31, cost 6362 95% CI 5642-7083). CONCLUSIONS: Cardiac damage can be evaluated using diagnostic codes in patients with AS and it is associated with in-hospital mortality, LoS and cost, and has more impact on these outcomes in patients treated with SAVR versus those treated with TAVR.
No takes yet. Share an insight, caveat, or question.
Kwok et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: